Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Neurology Journal
Published online: May 10, 2017
DOI: http://dx.doi.org/10.1212/WNL.0000000000004003
Fabrizio Stocchi, MD, PhD, Olivier Rascol, MD, Robert A. Hauser, MD, MBA, Susan Huyck, DrPH, Anjela Tzontcheva, PhD, Rachel Capece, BS, Tony W. Ho, MD, Peter Sklar, MD, MPH, Christopher Lines, PhD, David Michelson, MD and David J. Hewitt, MD
Objective: To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic drug for the treatment of Parkinson disease (PD) when given as monotherapy.
Methods: This was a randomized, 26-week, placebo- and active-controlled, parallel-group, multicenter, double-blind trial conducted in adults diagnosed with PD for <5 years who were not yet receiving L-dopa or dopamine agonists. Patients with a Unified Parkinson’s Disease Rating Scale…
